LCT waiting for minister
Thursday, 26 June, 2008
Living Cell Technologies (ASX: LCT) expects to hear on or after August 8 whether it can proceed with a New Zealand trial of its encapsulated porcine islet cell product, DiabeCell.
The New Zealand Minister for Health, David Cunliffe, has sought independent advice from the country's National Health Committee (NHC) on whether to authorise the phase I/IIa clinical trial.
LCT said in a statement it had already received approval from NZ regulatory bodies such as the regional ethics committee, the Gene Technology Advisory Committee and International Accreditation New Zealand.
It has also received approval from Medsafe, the regulatory body that approved the manufacture for human use of encapsulated porcine cells.
LCT is currently running a small clinical trial at the Sklifosovsky Institute in Moscow.
Organoid platform enables closer study of bat-borne viruses
Reconstructing bat organ physiology in the lab lets scientists explore how zoonotic viruses work...
Global study finds 250 genes linked to OCD
Researchers say they have found the genes linked to obsessive compulsive disorder (OCD), after...
TGA approves therapy for paediatric growth hormone deficiency
The TGA has approved SKYTROFA as a treatment for growth failure in children and adolescents aged...
